Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ABUS
stocks logo

ABUS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
599.59K
-61.78%
-0.035
-49.93%
399.96K
-77.32%
-0.040
-69.28%
199.62K
-98.15%
-0.040
-498.15%
Estimates Revision
The market is revising Downward the revenue expectations for Arbutus Biopharma Corporation (ABUS) for FY2025, with the revenue forecasts being adjusted by -4.76% over the past three months. During the same period, the stock price has changed by 5.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-4.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.43%
In Past 3 Month
Stock Price
Go Up
up Image
+5.00%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Arbutus Biopharma Corp (ABUS.O) is -28.35, compared to its 5-year average forward P/E of -8.39. For a more detailed relative valuation and DCF analysis to assess Arbutus Biopharma Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.39
Current PE
-28.35
Overvalued PE
-1.95
Undervalued PE
-14.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.11
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.36
Undervalued EV/EBITDA
-7.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
79.32
Current PS
0.00
Overvalued PS
202.83
Undervalued PS
-44.18
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ABUS News & Events

Events Timeline

(ET)
2025-11-13
07:37:10
Arbutus Biopharma announces Q3 earnings per share of 4 cents, below consensus estimate of 5 cents.
select
2025-10-07 (ET)
2025-10-07
08:21:10
Arbutus Biopharma to showcase imdusiran and AB-101 findings at The Liver Meeting 2025
select
2025-08-06 (ET)
2025-08-06
07:32:01
Arbutus Biopharma reports Q2 EPS 1c vs (11c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-15Benzinga
Chardan Capital Reaffirms Buy Rating for Arbutus Biopharma with $5 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and information.

  • Market Winning Tools: The platform is designed to help traders make informed decisions and enhance their trading success.

[object Object]
Preview
9.5
08-07NASDAQ.COM
Arbutus (ABUS) Q2 Revenue Surges 529%

  • Q2 2025 Financial Performance: Arbutus Biopharma reported a significant increase in GAAP revenue to $10.7 million, surpassing expectations due to a one-time recognition of deferred revenue from the termination of its Qilu partnership, resulting in a GAAP EPS of $0.01 and a net income of $2.5 million.

  • Strategic Focus and Challenges: The company is concentrating on advancing late-stage clinical development for its therapies while managing costs through restructuring; however, ongoing legal disputes regarding its LNP technology could impact future financial results.

[object Object]
Preview
9.5
08-06NASDAQ.COM
Arbutus Biopharma Corp. Q2 Earnings Summary

  • Earnings Performance: Arbutus Biopharma Corp. reported earnings of $2.523 million in Q2, a significant improvement from a loss of $19.796 million in the same period last year, with EPS rising to $0.01 from -$0.11.

  • Revenue Growth: The company's revenue increased to $10.739 million in Q2 compared to $1.726 million in the previous year, leading to a pre-market stock price increase of 3.81% to $3.540 on Nasdaq.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arbutus Biopharma Corp (ABUS) stock price today?

The current price of ABUS is 4.41 USD — it has decreased -0.45 % in the last trading day.

arrow icon

What is Arbutus Biopharma Corp (ABUS)'s business?

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

arrow icon

What is the price predicton of ABUS Stock?

Wall Street analysts forecast ABUS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABUS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arbutus Biopharma Corp (ABUS)'s revenue for the last quarter?

Arbutus Biopharma Corp revenue for the last quarter amounts to 529.00K USD, decreased -60.49 % YoY.

arrow icon

What is Arbutus Biopharma Corp (ABUS)'s earnings per share (EPS) for the last quarter?

Arbutus Biopharma Corp. EPS for the last quarter amounts to -0.04 USD, decreased -60.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arbutus Biopharma Corp (ABUS)'s fundamentals?

The market is revising Downward the revenue expectations for Arbutus Biopharma Corporation (ABUS) for FY2025, with the revenue forecasts being adjusted by -4.76% over the past three months. During the same period, the stock price has changed by 5.00%.
arrow icon

How many employees does Arbutus Biopharma Corp (ABUS). have?

Arbutus Biopharma Corp (ABUS) has 44 emplpoyees as of December 05 2025.

arrow icon

What is Arbutus Biopharma Corp (ABUS) market cap?

Today ABUS has the market capitalization of 848.15M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free